Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands.

Autor: Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG, Piening, Sigrid, Haaijer-Ruskamp, Flora M, de Graeff, Pieter A, Straus, Sabine M J M, Mol, Peter G M

Publikováno v: Drug Safety; 2012, Vol. 35 Issue 11, p1061-1072, 12p

Impact of safety-related regulatory action on clinical practice: a systematic review.

Autor: Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG, Piening, Sigrid, Haaijer-Ruskamp, Flora M, de Vries, Jonie T N, van der Elst, Menno E, de Graeff, Pieter A, Straus, Sabine M J M, Mol, Peter G M

Publikováno v: Drug Safety; 2012, Vol. 35 Issue 5, p373-385, 13p

Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands.

Autor: Dequito AB, Mol PG, van Doormaal JE, Zaal RJ, van den Bemt PM, Haaijer-Ruskamp FM, Kosterink JG, Dequito, Aileen B, Mol, Peter G M, van Doormaal, Jasperien E, Zaal, Rianne J, van den Bemt, Patricia M L A, Haaijer-Ruskamp, Flora M, Kosterink, Jos G W

Publikováno v: Drug Safety; 2011, Vol. 34 Issue 11, p1089-1100, 12p

Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010.

Autor: Bahri P, Mol PG, Théophile H, Edwards IR, Hugman BP, Bahri, Priya, Mol, Peter G M, Théophile, Hélène, Edwards, I Ralph, Hugman, Bruce P J

Publikováno v: Drug Safety; 2011, Vol. 34 Issue 10, p881-882, 2p

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance.

Autor: Bahri P; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland. priya.bahri@ema.europa.eu.; European Medicines Agency (EMA) (Coordinator of the ISoP CommSIG in Her Personal Capacity), Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands. priya.bahri@ema.europa.eu., Bowring G; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.; Uppsala Monitoring Centre (UMC), Uppsala, Sweden., Edwards BD; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.; Husoteria Ltd, Ashtead, UK., Anton C; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.; West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK., Aronson JK; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK., Caro-Rojas A; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.; Pontificia Universidad Javeriana, Bogotá, Colombia., Hugman BPJ; Oxford, UK., Mol PG; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands., Trifirò G; Department of Diagnostics and Public Health, University of Verona, Verona, Italy., Ilic K; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.; Takeda, Cambridge, MA, USA., Daghfous R; Tunisian National Centre of Pharmacovigilance, Tunis, Tunisia., Fermont I; Israel Society for Medication and Vaccine Safety (ERANIM), Jerusalem, Israel., Furlan G; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.; Pfizer s.r.l., Safety Surveillance and Risk Management, Milan, Italy., Gaissmaier W; Department of Psychology, Social Psychology and Decision Sciences, University of Konstanz, Konstanz, Germany., Geer MI; Department of Pharmaceutical Sciences, University of Kashmir, Srinagar, India., Hartigan-Go KY; Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.; School of Government, Ateneo De Manila University, Quezon City, Philippines., Houÿez F; European Organisation for Rare Diseases (EURORDIS), Paris, France., Neth H; Department of Psychology, Social Psychology and Decision Sciences, University of Konstanz, Konstanz, Germany., Norgela G; Uppsala Monitoring Centre (UMC), Uppsala, Sweden., Oppamayun Y; Thai Food and Drug Administration, Health Product Vigilance Center, Bangkok, Thailand., Raynor DKT; School of Healthcare, University of Leeds, Leeds, UK., Bouhlel M; Tunisian National Centre of Pharmacovigilance, Tunis, Tunisia.; Department of Pharmacology, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia., Santoro F; Uppsala Monitoring Centre (UMC), Uppsala, Sweden., Sultana J; Pharmacy Department, Mater Dei Hospital, Msida, Malta.

Publikováno v: Drug safety [Drug Saf] 2023 Jun; Vol. 46 (6), pp. 517-532. Date of Electronic Publication: 2023 May 23.